DENTSPLY SIRONA Inc.

Current report (Form 8-K) · Jun 4, 2026 · Item 5.07

Company

Documents

Primary topic

Item 5.07

Filed

Jun 4, 2026

Filing summary Workforce analysis SEC documents(6)Filing text

Type

8-K

File

xray-20260602.htm

Document text
8-K · xray-20260602.htm iXBRL 0000818479 2026-06-02 2026-06-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 2, 2026 Date of Report (Date of earliest event reported) DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) Delaware 0-16211 39-1434669 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 13320 Ballantyne Corporate Place, Charlotte North Carolina 28277-3607 (Address of Principal Executive Offices) (Zip Code) ( 844) 848-0137 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share XRAY The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.07 Submission of Matters to a Vote of Security Holders The annual meeting of stockholders (the “Annual Meeting”) of DENTSPLY SIRONA Inc. (the “Company”) was held on June 2, 2026. The following matters were voted upon at the Annual Meeting, with the results indicated: 1. Election of twelve directors to serve until the next annual meeting of stockholders or until their respective successors are duly elected and qualified. Director For Against Abstain Broker Non-Votes 1a. Michael J. Barber 167,115,711 642,651 82,953 14,762,922 1b. James D. Forbes 167,030,832 726,831 83,652 14,762,922 1c. Brian T. Gladden 167,131,075 633,358 76,882 14,762,922 1d. Betsy D. Holden 144,275,619 23,407,281 158,415 14,762,922 1e. Clyde R. Hosein 166,571,426 1,166,383 103,506 14,762,922 1f. Gregory T. Lucier 164,966,222 2,723,724 151,369 14,762,922 1g. Jonathan J. Mazelsky 164,501,688 3,177,506 162,121 14,762,922 1h. Brian P. McKeon 167,101,344 657,813 82,158 14,762,922 1i. Daniel T. Scavilla 167,087,998 674,884 78,433 14,762,922 1j. Leslie F. Varon 166,054,818 1,611,470 175,027 14,762,922 1k. Janet S. Vergis 165,269,825 2,490,769 80,721 14,762,922 1l. Donald J. Zurbay 116,568,821 51,059,271 213,223 14,762,922 2. Ratification of appointment of Deloitte and Touche LLP as the Company’s independent registered public accountants for 2026. For Against Abstain Broker Non-Votes 182,033,381 465,064 105,792 — 3. Approval, by non-binding advisory vote, of the Company’s executive compensation for 2025. For Against Abstain Broker Non-Votes 158,496,058 9,090,084 255,173 14,762,922 4. Approval of Amendment No. 2 to the Company’s 2024 Omnibus Incentive Plan (the “2024 Plan”) to increase the number of shares of the Company’s Common Stock issuable under the 2024 Plan by 15,000,000 shares. For Against Abstain Broker Non-Votes 139,933,388 27,713,777 194,150 14,762,922 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENTSPLY SIRONA Inc. By: /s/ Daniel T. Scavilla Daniel T. Scavilla President and Chief Executive Officer Date: June 4, 2026

Document text

8-K · xray-20260602.htm iXBRL

0000818479 2026-06-02 2026-06-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

June 2, 2026
Date of Report (Date of earliest event reported)

DENTSPLY SIRONA Inc.
(Exact name of registrant as specified in its charter)
Delaware
0-16211 39-1434669

(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)

13320 Ballantyne Corporate Place,
Charlotte
North Carolina
28277-3607

(Address of Principal Executive Offices)
(Zip Code)

( 844) 848-0137
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.01 per share XRAY The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o

Item 5.07 Submission of Matters to a Vote of Security Holders

The annual meeting of stockholders (the “Annual Meeting”) of DENTSPLY SIRONA Inc. (the “Company”) was held on June 2, 2026. The following matters were voted upon at the Annual Meeting, with the results indicated:

1. Election of twelve directors to serve until the next annual meeting of stockholders or until their respective successors are duly elected and qualified.
Director
For
Against
Abstain
Broker Non-Votes

1a.
Michael J. Barber 167,115,711 642,651 82,953 14,762,922
1b.
James D. Forbes 167,030,832 726,831 83,652 14,762,922
1c.
Brian T. Gladden 167,131,075 633,358 76,882 14,762,922
1d.
Betsy D. Holden 144,275,619 23,407,281 158,415 14,762,922
1e.
Clyde R. Hosein 166,571,426 1,166,383 103,506 14,762,922
1f.
Gregory T. Lucier 164,966,222 2,723,724 151,369 14,762,922
1g.
Jonathan J. Mazelsky 164,501,688 3,177,506 162,121 14,762,922
1h.
Brian P. McKeon 167,101,344 657,813 82,158 14,762,922
1i.
Daniel T. Scavilla 167,087,998 674,884 78,433 14,762,922
1j.
Leslie F. Varon 166,054,818 1,611,470 175,027 14,762,922
1k. Janet S. Vergis 165,269,825 2,490,769 80,721 14,762,922
1l. Donald J. Zurbay 116,568,821 51,059,271 213,223 14,762,922

2. Ratification of appointment of Deloitte and Touche LLP as the Company’s independent registered public accountants for 2026.
For
Against
Abstain
Broker Non-Votes

182,033,381 465,064 105,792 —

3. Approval, by non-binding advisory vote, of the Company’s executive compensation for 2025.
For
Against
Abstain
Broker Non-Votes

158,496,058 9,090,084 255,173 14,762,922

4. Approval of Amendment No. 2 to the Company’s 2024 Omnibus Incentive Plan (the “2024 Plan”) to increase the number of shares of the Company’s Common Stock issuable under the 2024 Plan by 15,000,000 shares.
For
Against
Abstain
Broker Non-Votes

139,933,388 27,713,777 194,150 14,762,922

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DENTSPLY SIRONA Inc.

By: /s/ Daniel T. Scavilla

Daniel T. Scavilla
President and Chief Executive Officer

Date: June 4, 2026

Open on SEC

All SEC filings Signals